【文章內(nèi)容簡(jiǎn)介】 Line Treatment in Advanced or Metastatic Breast Cancer (MBC), A Phase II Study. RESULTS: CR:% PR40% SD: % ORR: %. MTTP: 7 months The overall survival at 1 and 2 years was % and %。 El Serafi MM, et al. J Egypt Natl Canc Inst. 2022。18(3):209215. Gemcitabine in the management of metastatic breast cancer: a systematic review. 共 83個(gè)試驗(yàn) ，包括 4個(gè) III 期隨機(jī)臨床試驗(yàn)，全部 III 期臨床試驗(yàn)均為一線用藥。 結(jié)果：其中 2個(gè) III期試驗(yàn)證明含 gemcitabine方案治療MBC療效高，副作用小。而另外 2個(gè) III期試驗(yàn)卻 認(rèn)為沒有臨床受益，而副作用大。 結(jié)論 : Gemcitabine ＋ taxane一線或二線治療 MBC療效顯著。 Dent S, et al. Breast Cancer Res Treat. 2022 Low dose Gemcitabine plus cisplatin in a weeklybased regimen as salvage therapy for relapsed breast cancer after taxaneanthracyclinecontaining regimens. gemcitabine (G) (initial dose 750 mg/m(2), or 600 mg/m(2) if the patient had received more than two previous CT lines) plus cisplatin (P) (initial dose 30 mg/m(2), or 20 mg/m(2) in case of /=3 prior CT lines) on days 1 and 8 of a 21day cycle. Treatment was postponed to day 15 if it could not be given on day 8, without dose reduction. If treatment could not be given on day 15, a 20% dose reduction was allowed and treatment given the next week. S225。nchezEscribano Morcuende R, et al. Clin Transl Oncol. 2022。 9(7):459464. Low dose Gemcitabine plus cisplatin in a weeklybased regimen as salvage therapy for relapsed breast cancer after taxaneanthracyclinecontaining regimens. All had prior anthracyclines and taxanes. Other agents used included 5FU/eniluracil, MTX, RPR 109881A, trastuzumab, cisplatin, VP16, vinorelbine, capecitabine and irinotecan. % had received radiotherapy % hormonal therapy. S225。nchezEscribano Morcuende R, et al. Clin Transl Oncol. 2022。 9(7):459464. Low dose Gemcitabine plus cisplatin in a weeklybased regimen as salvage therapy for relapsed breast cancer after taxaneanthracyclinecontaining regimens. Results: PR: %, SD: %. Clinical Benefit Rate (PR+SD): % MTTP: 4 months Median survival: 8 months Toxicities grade 3 were neutropenia 35% and thrombocytopenia 15%. S225。nchezEscribano Morcuende R, et al. Clin Transl Oncol. 2022。 9(7):459464. Low dose Gemcitabine plus cisplatin in a weeklybased regimen as salvage therapy for relapsed breast cancer after taxaneanthracyclinecontaining regimens. 結(jié)論 : 曾進(jìn)行過多次化療的， PS較好的 MBC. 每周一次的 cisplatingemcitabine 是安全有效的挽救治療方案。 S225。nchezEscribano Morcuende R, et al. Clin Transl Oncol. 2022。 9(7):459464. Dosefinding study of capecitabine in bination with weekly paclitaxel for patients with anthracyclinepretreated metastatic breast cancer. CONCLUSION: capecitabine 1,000 mg/m(2) twice daily, days 114, paclitaxel 60 mg/m(2)/week. paclitaxel 劑量大于 60 mg/m(2)/week 是不合適的，因出現(xiàn)嚴(yán)重的皮膚毒性。 Susnjar S, et al. J BUON. 2022。12(2):189196. A phase II study of trastuzumab and capecitabine for patients with HER2overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. 59 例病人由 6 個(gè)中心提供。進(jìn)行 trastuzumab ＋ capecitabine治療乳腺癌的研究。 86％接受過化療 。 CMF (%), anthracyclines (%), taxanes (%), 或兩種方案化療 (%)。 Yamamoto D, et al. Cancer Chemother Pharmacol. 2022 . A phase II study of trastuzumab and capecitabine for patients with HER2overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. RR： % (trastuzumab + capecitabine 作為 MBC的一線治療 ) ，有效者 % 在HER2 +3的患者中 , 二線或三線治療者也有許多有效。 trastuzumab ＋ capecitabine 作為一線治療比作為二、三線治療有更長(zhǎng)的 TTP 和 OS。 Yamamoto D, et al. Cancer Chemother Pharmacol. 2022 . Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. 27例 HER2過度表達(dá)的 MBC，曾用 anthracyclines and/or taxanes 治療，給予口服capecitabine 1,250 mg/m(2)， bid， 1－ 14 天。 trastuzumab 4 mg/kg ，第 1天，以后每周 2 mg/kg。 RR: 45%, CR: 15%, PR:30%. SD: 33%. MOS: 28 M. MPFS: M. Schaller G, et al. J Clin Oncol. 2022。25(22):324650. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment. Cisplatin : 75 mg/m2 on day 1 VNR: 25 mg/m2 on days 1 , 8 every 3 weeks. CR: % 。 PR: %。 OR: % neutropenia grade 190。 : 47%. Thrombocytopenia grade 3/4 :11%. There were no treatmentrelated deaths. Vassilomanolakis M, et al. Cancer Invest. 2022。21(4):497504. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment. 結(jié)論 : DDP / VNR 耐受好，且對(duì) anthracyclines 和 docetaxel 耐藥的病人有效。 . Vassilomanolakis M, et al. Cancer Invest. 2022。21(4):497504. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. trastuzumab with weekly vinorelbine therapy or weekly taxane therapy (paclitaxel or docetaxel at the investigator39。s choice). Burstein HJ, et al. Cancer. 2